Life Sciences AISeries BWorkflowℹOwkin
AI-led scientific workflows can connect patient evidence to testable hypotheses, with biomedical experts and wet labs validating promising results.
Company snapshot
- Stage
- Series B
- Funding
- Series B (aggregate disclosed) · $230M
- Status
- published
- Updated
- Nov 8, 2026
- Views
- Category
- Life Sciences AI
- Website
- owkin.com
What they're building
AI-led scientific workflows can connect patient evidence to testable hypotheses, with biomedical experts and wet labs validating promising results. Owkin develops K Pro, an autonomous AI scientist that combines multimodal patient data, specialized agents, and laboratory validation to investigate biomedical questions.
Founders
Thomas Clozel
Co-founder
Gilles Wainrib
Co-founder
Foundation model usage
Editorial estimates from product descriptions. Model providers and actual usage are not confirmed.
- Inferred architecture
- Consumer inference, Agentic loops, Multimodal processing
- Estimated model demand
- Very high intensity
NYC footprint
- NYC office
- 119 West 24th Street, Floor 4, New York, NY 10011
Funding
Latest funding: Series B (aggregate disclosed) · $230M. Total raised: $304.1M.
Sources & location evidence
Open research desk ↗Profile source review: 2026-11-04. Current official press kit lists Series B funding of $230M and total funding of $304.1M. These are disclosed aggregate figures on an undated page, not a single dated new financing announcement. No exact round date or lead investor is invented. Its 2022 Bristol Myers Squibb deal combines an equity investment with an upfront collaboration payment; the full $80M is not treated as pure equity. Current primary contact page lists the New York office. No global headquarters claim is made. Copy is synthesized from cited first-party messaging; no independent performance validation is implied.
- https://www.owkin.com/ ↗
- https://www.owkin.com/press-kit ↗
- https://www.owkin.com/contact ↗
- https://www.owkin.com/faqs/how-much-investment-has-owkin-recieved ↗
Manhattan · verified office
119 West 24th Street, Floor 4, New York, NY 10011. Current company contact page explicitly lists New York among its office locations and supplies the street/floor. This is public business-contact evidence, not a legal filing or private address. Page is undated. No neighborhood or global-headquarters label inferred.
Contact Us - Owkin ↗Source checked 2026-11-04
Notes
Owkin is tagged workflow based on buyer clarity, repeat workflow activity, public activity, and fit with the AI Atlas map.
Related NYC startups
Proxima Bio, formerly VantAI, is an AI-native platform for proximity-based drug discovery, mapping protein-protein interactions to design medicines that reshape protein networks rather than inhibit single targets.
Life Sciences AIWorkflowℹRecent Activity
Scientific AI can become more useful by learning the mechanisms behind complex systems and using those explanations to guide new investigations.
Output Labs develops AI systems for mechanistic reasoning, aiming to model how complex systems work and apply those explanations to scientific problems.
Life Sciences AIWorkflowℹRecent Activity
Find therapeutic targets hidden in RNA splicing.
Envisagenics analyzes RNA splicing with AI to identify disease-specific drug targets, advancing therapeutic discovery for cancer and neurodegenerative conditions through its SpliceCore platform.
Life Sciences AIInfraℹRecent Activity